● Recruiting

Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL

Condition: Diffuse Large B-cell Lymphoma(DLBCL) · Sponsor: The First Affiliated Hospital of Soochow University

PhasePhase 2

Planned participants40

Who can joinAll sexes, 18 Years to 70 Years

Healthy volunteersNo

About this study

The objective of this study is to evaluate the efficacy and safety of the Glofitamab bridging ASCT regimen in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and to provide better clinical benefits to these patients.

This description comes directly from the study's public registry record.

Talk to the study team

Zhengming Jin · 67781856 · jinzhengming519519@163.com

Changju Qu · 67781856 · qcj310@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06682130